Corient Private Wealth LP Takes Position in Boston Scientific Corporation $BSX

Key Points

• Corient Private Wealth initiated a Boston Scientific position by purchasing 287,815 shares valued at approximately $11.24 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific exceeded quarterly expectations, reporting $0.86 in adjusted EPS and $5.44 billion in revenue, with revenue rising 7.5% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $71.62.
• The company authorized a $5 billion share-repurchase program, while insiders also bought shares recently, including purchases by directors David Habiger and Edward Ludwig.

Corient Private Wealth LP bought a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 287,815 shares of the medical equipment provider's stock, valued at approximately $11,241,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Kelleher Financial Advisors purchased a new stake in Boston Scientific in the 2nd quarter worth $25,000. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the 2nd quarter valued at about $26,000. Swiss RE Ltd. purchased a new position in shares of Boston Scientific during the fourth quarter valued at about $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific during the fourth quarter valued at about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Boston Scientific in the first quarter worth about $28,000. Institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on BSX. BTIG Research decreased their target price on Boston Scientific from $65.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday, July 29th. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a report on Thursday, May 28th. Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a research note on Wednesday, July 29th. Jefferies Financial Group decreased their price objective on Boston Scientific from $100.00 to $67.00 and set a "buy" rating on the stock in a report on Wednesday, June 24th. Finally, Weiss Ratings downgraded Boston Scientific from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Tuesday, July 7th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $71.62.

Boston Scientific Stock Up 0.3%

Shares of NYSE:BSX opened at $46.82 on Friday. The company has a market cap of $67.85 billion, a price-to-earnings ratio of 18.96, a PEG ratio of 1.02 and a beta of 0.56. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average price of $46.56 and a 200 day moving average price of $56.65.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. During the same period in the previous year, the firm posted $0.75 earnings per share. The firm's revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has initiated a stock buyback program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's management believes its shares are undervalued.

Insider Transactions at Boston Scientific

In related news, Director David C. Habiger purchased 2,100 shares of the stock in a transaction that occurred on Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Edward J. Ludwig acquired 5,000 shares of the company's stock in a transaction on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares of the company's stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders purchased 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source